BridgeBio Pharma Inc
NASDAQ:BBIO
Earnings Announcements
BridgeBio Pharma Reports First Quarter 2022 Financial Results
Published: 05/05/2022 11:48 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Reports First Quarter 2022 Financial Results and Business Update.
Ended Quarter With $633.5 Million in Cash, Cash Equivalents and Marketable Securities, Providing Financial Runway Into 2024.
Qtrly Net Loss per Share, Basic and Diluted $1.35.
Q1 Earnings per Share View $-1.11 -- Refinitiv Ibes Data (analyst estimates).
Ended Quarter With $633.5 Million in Cash, Cash Equivalents and Marketable Securities, Providing Financial Runway Into 2024.
Qtrly Net Loss per Share, Basic and Diluted $1.35.
Q1 Earnings per Share View $-1.11 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $15.42 Million
Adjusted EPS is expected to be -$0.85
Next Quarter Revenue Guidance is expected to be $27.76 Million
Next Quarter EPS Guidance is expected to be -$0.82
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.85
Next Quarter Revenue Guidance is expected to be $27.76 Million
Next Quarter EPS Guidance is expected to be -$0.82
More details on our Analysts Page.